| Q45069872 | A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis. |
| Q48342063 | A brief review on prognostic models of primary biliary cholangitis |
| Q35490131 | A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis |
| Q53591523 | A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. |
| Q73118377 | A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis |
| Q44825279 | A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results |
| Q44469322 | A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid. |
| Q51586165 | A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis |
| Q42545724 | A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease |
| Q38223869 | ALSUntangled no. 25: ursodiol |
| Q74044295 | Acute and chronic effects of different bile acids on indomethacin-induced intestinal inflammation |
| Q99550841 | An update on the management of cholestatic liver diseases |
| Q37980899 | Anti-fibrotic therapy: lost in translation? |
| Q33860403 | Anti-inflammatory effects of ursodeoxycholic acid by lipopolysaccharide-stimulated inflammatory responses in RAW 264.7 macrophages |
| Q39293482 | Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid |
| Q43760681 | Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? |
| Q34111559 | Autoantigens in primary biliary cirrhosis |
| Q92314377 | Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies |
| Q37760788 | Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis |
| Q34210595 | Benign recurrent intrahepatic cholestasis |
| Q60638070 | Benign recurrent intrahepatic cholestasis |
| Q91431676 | Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis |
| Q33591450 | Bile acid abnormalities in cholestatic liver diseases |
| Q77738413 | Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid-regulated ductal secretion |
| Q39145368 | Bile acids and cardiovascular function in cirrhosis. |
| Q41763144 | Bile salt inhibition of host cell damage by Clostridium difficile toxins |
| Q41050507 | Bile secretion--models, mechanisms, and malfunctions. A perspective on the development of modern cellular and molecular concepts of bile secretion and cholestasis |
| Q64048538 | Biliary atresia |
| Q34108895 | Biliary physiology and disease: reflections of a physician-scientist |
| Q70871974 | Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment |
| Q33641759 | Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study |
| Q46408092 | Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis |
| Q37855976 | Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis |
| Q33723821 | Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. |
| Q38456383 | Blood cytokine, chemokine and gene expression in cholestasis patients with intractable pruritis treated with a molecular adsorbent recirculating system: a case series |
| Q64898654 | CYP2E1 and CYP3A1/2 gene expression is not associated with the ursodeoxycholate effect on ethanol-induced lipoperoxidation. |
| Q41836065 | Cell volume and bile acid excretion |
| Q39490877 | Cetirizine Pharmacokinetics and Pharmacodynamics in Primary Biliary Cirrhosis |
| Q34408204 | Characterisation of patients with a complete biochemical response to ursodeoxycholic acid |
| Q77164927 | Cholestasis confers resistance to the rat liver mitochondrial permeability transition |
| Q70670252 | Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis |
| Q33870255 | Chronic cholestatic diseases |
| Q33879944 | Chronic graft-versus-host disease: is there an alternative to the conventional treatment? |
| Q67577086 | Chronic graft-vs.-host disease of the liver: another indication of ursodeoxycholic acid? |
| Q36127473 | Chronic liver disease. The scope of causes and treatments |
| Q28070154 | Cirrhosis and autoimmune liver disease: Current understanding |
| Q77221662 | Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group |
| Q37182934 | Clinical features and management of primary biliary cirrhosis. |
| Q53008590 | Clinical significance of recurrent primary biliary cirrhosis after liver transplantation. |
| Q77716502 | Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis |
| Q37570952 | Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis |
| Q44230338 | Colestimide: the efficacy of a novel anion-exchange resin in cholestatic disorders |
| Q44487597 | Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis |
| Q77872001 | Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial |
| Q26765804 | Controversies in the management of primary sclerosing cholangitis |
| Q46358351 | Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy |
| Q50636830 | Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. |
| Q35068031 | Current management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q38055205 | Current pharmacotherapy for cholestatic liver disease |
| Q34408950 | Current status of therapy in autoimmune liver disease |
| Q73130933 | Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study |
| Q38266358 | Diagnosis and management of primary biliary cirrhosis |
| Q41109695 | Diagnosis and therapy of cholestatic liver disease |
| Q54035457 | Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease. |
| Q72108717 | Differential effects of chenodeoxycholic and ursodeoxycholic acids on expression of procoagulant activity by human monocytes |
| Q68019505 | Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes |
| Q34687676 | Drug therapy of primary biliary diseases: classical and modern strategies. |
| Q46049458 | Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis |
| Q51226271 | Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis. |
| Q42254171 | Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages |
| Q45045457 | Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis |
| Q33623681 | Effect of rifampicin in the treatment of pruritus in hepatic cholestasis |
| Q73740428 | Effect of sodium tauroursodeoxycholate (UR-906) on liver dysfunction in bile duct-ligated rats |
| Q74429593 | Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes |
| Q42977234 | Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C. |
| Q72503309 | Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period |
| Q72736523 | Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis |
| Q93046523 | Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials |
| Q71598528 | Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study |
| Q71882287 | Effects of chenodeoxycholic and ursodeoxycholic acids on interferon-gamma production by peripheral blood mononuclear cells from patients with primary biliary cirrhosis |
| Q71823028 | Effects of oral ursodeoxycholic acid in healthy cats on clinicopathological parameters, serum bile acids and light microscopic and ultrastructural features of the liver |
| Q42280172 | Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis |
| Q42276877 | Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture |
| Q71535252 | Effects of ursodeoxycholic acid and chenodeoxycholic acid on major histocompatibility complex class I gene expression |
| Q37352458 | Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial |
| Q83200621 | Efficacy of ursodeoxycholic acid combined with Tongdan Decoction () on immunological indices and histopathological changes in primary biliary cirrhosis patients |
| Q73167014 | Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study |
| Q92864604 | Emerging therapies for PBC |
| Q47348031 | Empirical and normative aspects of medical technology assessment. The case of reduced-size liver transplantations with living donors |
| Q51137626 | Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. |
| Q30539166 | Evolving therapies for liver fibrosis |
| Q36119487 | Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy |
| Q77586211 | Fatigue in primary biliary cirrhosis |
| Q40547217 | Feline cholangiohepatitis complex |
| Q44070526 | Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-kappaB activation |
| Q36368951 | Fibrogenesis in cirrhosis. Potential for therapeutic intervention |
| Q72131189 | Functional and ultrastructural features of ethanol/bile salts interaction in the isolated perfused rat liver |
| Q39213467 | Geoepidemiology and changing mortality in primary biliary cholangitis |
| Q34109467 | Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium |
| Q73975311 | Glycochenodeoxycholic acid (GCDC) induced hepatocyte apoptosis is associated with early modulation of intracellular PKC activity |
| Q35734592 | Granulomatous liver disease and cholestasis |
| Q56429943 | Guidelines for the management of primary biliary cirrhosis |
| Q36848614 | HPLC-fluorescence determination of individual free and conjugated bile acids in human serum |
| Q44224842 | Hepatic graft-versus-host disease resembling acute hepatitis: additional treatment with ursodeoxycholic acid |
| Q37629675 | Hepatic inflammation and progressive liver fibrosis in chronic liver disease |
| Q40434271 | Hepatobiliary pruritus: What are effective treatments? |
| Q44949314 | Hepatobiliary transporters: from genomics to diseases |
| Q40649152 | Hepatoprotection by hydrophilic bile salts |
| Q57113939 | High Dose and Delayed Treatment with Bile Acids Ineffective in RML Prion-Infected Mice |
| Q74645177 | Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression |
| Q42561623 | How we have learned about the complexity of physiology, pathobiology and pharmacology of bile acids and biliary secretion |
| Q54633892 | Hydrophobic bile salt inhibits bacterial adhesion on biliary stent material. |
| Q68225187 | Immunomodulatory effects of ursodeoxycholic acid on immune responses |
| Q71752162 | Immunopathology of primary biliary cirrhosis |
| Q44512233 | Immunosuppressive therapy for primary biliary cirrhosis: Do we need in future? |
| Q36767051 | Immunosupressive therapy for primary biliary cirrhosis |
| Q46907665 | Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis |
| Q33579196 | Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis |
| Q39385176 | Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis |
| Q44139912 | Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis |
| Q72048502 | Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat |
| Q42547655 | Improvement of estradiol-17 beta-D-glucuronide-induced cholestasis by sodium tauroursodeoxycholate therapy in rats |
| Q36682798 | Incidence, mortality, and predictive factors of hepatocellular carcinoma in primary biliary cirrhosis |
| Q77373443 | Influence of cholestasis on absorption of ursodeoxycholic acid |
| Q41101467 | Interferon and other therapies for hepatitis B and hepatitis C infections. |
| Q44111064 | Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate |
| Q44429825 | Involvement of integrins and Src in tauroursodeoxycholate-induced and swelling-induced choleresis |
| Q36807116 | Is there a role for cyclophilin inhibitors in the management of primary biliary cirrhosis? |
| Q72001802 | Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease? |
| Q51597193 | Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. |
| Q37738636 | Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis |
| Q73715566 | Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver |
| Q74529900 | Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis |
| Q33698914 | Loss of Inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis |
| Q55498617 | Magnetic resonance imaging evidence of hippocampal structural changes in patients with primary biliary cholangitis. |
| Q33999149 | Management of graft-versus-host disease in paediatric bone marrow transplant recipients |
| Q35573921 | Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis |
| Q79222550 | Management of primary biliary cirrhosis |
| Q35960781 | Management of primary biliary cirrhosis and autoimmune cholangitis |
| Q34027995 | Management of primary biliary cirrhosis: from diagnosis to end-stage disease |
| Q40140683 | Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines |
| Q33591454 | Mechanism of hepatoprotective action of bile salts in liver disease |
| Q35734498 | Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease |
| Q34936618 | Medical and economic impact of autoimmune hepatitis |
| Q34017604 | Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets |
| Q43226120 | Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. |
| Q42278397 | Metabolism, pharmacokinetics, and activity of a new 6-fluoro analogue of ursodeoxycholic acid in rats and hamsters |
| Q46775425 | Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis |
| Q44278008 | Mitochondrially mediated synergistic cell killing by bile acids. |
| Q50130002 | Modern treatment of primary biliary cholangitis |
| Q46102659 | Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid |
| Q46719878 | Mortality attributable to cholestatic liver disease in the United States. |
| Q37355843 | Natural history and management of primary biliary cirrhosis |
| Q46608065 | Natural history of primary biliary cirrhosis |
| Q44797529 | Natural history of pruritus in primary biliary cirrhosis |
| Q92565000 | Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics |
| Q26824664 | Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis |
| Q33719505 | New approaches to understanding the etiology and treatment of total parenteral nutrition-associated cholestasis |
| Q38261577 | New therapies for primary biliary cirrhosis |
| Q47223909 | New therapies target the toxic consequences of cholestatic liver disease |
| Q89623998 | New treatments/targets for primary biliary cholangitis |
| Q45279435 | No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis |
| Q34232039 | Novel approaches to the treatment of chronic graft-versus-host disease |
| Q36285749 | Novel insight into mechanisms of cholestatic liver injury |
| Q42375647 | Novel strategies and therapeutic options for the management of primary biliary cholangitis |
| Q39216355 | Old and new treatments for primary biliary cholangitis |
| Q28087211 | Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis |
| Q37963978 | Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis |
| Q34354186 | Options for treatment of primary biliary cirrhosis |
| Q73401694 | Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid |
| Q80089315 | Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH) |
| Q34623557 | Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches |
| Q38738566 | Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. |
| Q36669314 | Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents |
| Q42259932 | Phosphoinositide 3-kinase-dependent Ras activation by tauroursodesoxycholate in rat liver |
| Q72227193 | Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone |
| Q92731189 | Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis |
| Q41041031 | Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue |
| Q56337320 | Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score |
| Q33778884 | Preventive care in chronic liver disease |
| Q38651060 | Primary Biliary Cholangitis Alters Functional Connections of the Brain's Deep Gray Matter |
| Q90707736 | Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases |
| Q73246614 | Primary Biliary Cirrhosis |
| Q64234658 | Primary biliary cholangitis patients exhibit MRI changes in structure and function of interoceptive brain regions |
| Q54390436 | Primary biliary cholangitis: new treatments for an old disease. |
| Q56428273 | Primary biliary cirrhosis |
| Q56854243 | Primary biliary cirrhosis |
| Q57141930 | Primary biliary cirrhosis |
| Q84230884 | Primary biliary cirrhosis |
| Q85213554 | Primary biliary cirrhosis |
| Q38058979 | Primary biliary cirrhosis and bile acids |
| Q26853145 | Primary biliary cirrhosis and liver transplantation |
| Q34210604 | Primary biliary cirrhosis and primary sclerosing cholangitis |
| Q35609106 | Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. |
| Q26799419 | Primary biliary cirrhosis: From bench to bedside |
| Q34041388 | Primary biliary cirrhosis: What do autoantibodies tell us? |
| Q33869324 | Primary biliary cirrhosis: new perspectives in diagnosis and treatment |
| Q34515652 | Primary biliary cirrhosis: new thoughts on pathophysiology and treatment |
| Q43987255 | Primary biliary cirrhosis: proposal for a new simple histological scoring system |
| Q35573929 | Primary biliary cirrhosis: specific treatment |
| Q50068638 | Primary sclerosing cholangitis and primary biliary cirrhosis |
| Q41871213 | Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis |
| Q34636760 | Protective effect of Öküzgözü (Vitis vinifera L. cv.) grape juice against carbon tetrachloride induced oxidative stress in rats |
| Q40758275 | Protective effects of ursodeoxycholic acid on chenodeoxycholic acid-induced liver injury in hamsters |
| Q35573916 | Pruritus and fatigue in primary biliary cirrhosis |
| Q40801345 | Pruritus associated with cholestasis. A review of pathogenesis and management |
| Q33745849 | Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis |
| Q34464043 | Recent advances in the development of farnesoid X receptor agonists |
| Q42406650 | Recent developments in the management of idiopathic cholestatic liver disease |
| Q33730935 | Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant |
| Q41034426 | Regulation of plasma membrane localization of the Na+-taurocholate cotransporting polypeptide (Ntcp) by hyperosmolarity and tauroursodeoxycholate |
| Q72022177 | Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C |
| Q38174167 | Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q33723536 | Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases |
| Q35890613 | Revision and update on clinical practice guideline for liver cirrhosis. |
| Q72879601 | Serum bile acids and cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features |
| Q70670255 | Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy |
| Q72210545 | Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine |
| Q83232557 | Small-duct primary sclerosing cholangitis |
| Q41118802 | Study of human isoursodeoxycholic acid metabolism |
| Q73278883 | Suppressive effect of ursodeoxycholic acid on regenerating cells |
| Q40442161 | Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells |
| Q45074381 | Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment |
| Q71958797 | Synthesis of interleukin-1β in primary biliary cirrhosis: Relationship to treatment with methotrexate or colchicine and disease progression |
| Q72316239 | Tauro alpha-muricholate is as effective as tauro beta-muricholate and tauroursodeoxycholate in preventing taurochenodeoxycholate-induced liver damage in the rat |
| Q71171386 | Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study |
| Q77470564 | Tauroursodeoxycholic acid protects cholestasis in rat reperfused livers: its roles in hepatic calcium mobilization |
| Q33910573 | Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis |
| Q77807948 | Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group |
| Q64974270 | Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. |
| Q52624982 | The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. |
| Q28086803 | The Importance of Autoantibody Detection in Primary Biliary Cirrhosis |
| Q77758118 | The choleretic effects of N-acetylglucosaminides, major urinary metabolites of ursodeoxycholic acid, in bile fistula rats |
| Q73574823 | The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone |
| Q35833175 | The diagnosis and treatment of primary biliary cirrhosis |
| Q41980473 | The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis |
| Q46614923 | The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study |
| Q38017976 | The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis |
| Q50522495 | The inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP. |
| Q71185606 | The pruritus of cholestasis |
| Q70590270 | The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group |
| Q72371418 | The role of sodium in the uptake of ursodeoxycholic acid in isolated hamster hepatocytes |
| Q43589988 | The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice |
| Q34481547 | The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent |
| Q40974682 | The ursodeoxycholic acid story in primary biliary cirrhosis |
| Q39816216 | Therapeutic Equivalence of Ursodeoxycholic Acid Tablets and Ursodeoxycholic Acid Capsules for the Treatment of Primary Biliary Cirrhosis |
| Q27015735 | Therapeutic uses of animal biles in traditional Chinese medicine: an ethnopharmacological, biophysical chemical and medicinal review |
| Q34182672 | Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q77349117 | Treatment of autoimmune cholangitis |
| Q39314534 | Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review. |
| Q34027595 | Treatment of primary biliary cirrhosis and primary sclerosing cholangitis: use of ursodeoxycholic acid |
| Q43967448 | Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis |
| Q33873354 | URSO-panacea or placebo? |
| Q72371438 | UW-preservation of cultured human gallbladder epithelial cells: phenotypic alterations and differential mucin gene expression in the presence of bile |
| Q30522942 | Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. |
| Q55190939 | Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. |
| Q67993675 | Ursodeoxycholate has no beneficial effect on liver function or histology in biliary cirrhosis in the rat |
| Q72862935 | Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria |
| Q37617217 | Ursodeoxycholic Acid ameliorates pain severity and cartilage degeneration in monosodium iodoacetate-induced osteoarthritis in rats |
| Q34330984 | Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. |
| Q70680436 | Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis |
| Q36053433 | Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease. |
| Q44671802 | Ursodeoxycholic acid and histological progression in primary biliary cirrhosis |
| Q71605603 | Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis |
| Q42699503 | Ursodeoxycholic acid and primary biliary cirrhosis |
| Q71214957 | Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis |
| Q24197983 | Ursodeoxycholic acid for cystic fibrosis-related liver disease |
| Q24187304 | Ursodeoxycholic acid for cystic fibrosis-related liver disease |
| Q57126201 | Ursodeoxycholic acid for cystic fibrosis-related liver disease |
| Q33909429 | Ursodeoxycholic acid for cystic fibrosis-related liver disease. |
| Q24202184 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q24241945 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q44487653 | Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression |
| Q72789964 | Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC |
| Q54072767 | Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. |
| Q68019501 | Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial |
| Q42551875 | Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy |
| Q77598543 | Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications |
| Q40573407 | Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis |
| Q42541078 | Ursodeoxycholic acid increased bile flow and affects bile composition in the early postoperative phase following liver transplantation |
| Q53884158 | Ursodeoxycholic acid increases the activities of alkaline sphingomyelinase and caspase-3 in the rat colon. |
| Q52087593 | Ursodeoxycholic acid modulates cyclosporin A oral absorption in liver transplant recipients. |
| Q28371128 | Ursodeoxycholic acid prevents hepatic cytochrome P450 isozyme reduction in rats with deoxycholic acid-induced liver injury |
| Q43324910 | Ursodeoxycholic acid promotes intestinal adaptation in a cat model of short bowel syndrome. |
| Q44785865 | Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. |
| Q77386849 | Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses |
| Q51604167 | Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. |
| Q28377666 | Ursodeoxycholic acid therapy in hepatobiliary disease |
| Q40457634 | Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children |
| Q42551010 | Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study |
| Q71443635 | Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis |
| Q33866782 | Ursodeoxycholic acid treatment of vanishing bile duct syndromes |
| Q72347760 | Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial |
| Q34515643 | Use of ursodeoxycholic acid in patients with liver disease |
| Q52920374 | Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. |
| Q38252904 | Women and primary biliary cirrhosis |
| Q77790572 | [Liver transplantation in the adult: who and when to transplant?] |
| Q73650876 | [Usefulness of magnetic cholangioresonance in the study of hepatobiliary disease in patients adults with cystic fibrosis] |
| Q50492543 | α5 β1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes. |